Quotient is seeking a highly strategic, intellectually agile, and clinically minded leader to serve as Vice President of Translational Medicine. This is a senior clinical leadership role responsible for integrating clinical insights across scientific, drug discovery and corporate teams to support prioritization of disease areas, drug targets, medicine profiles, and leading early translational planning into clinical development strategies with a high probability of clinical and regulatory success.
The role will provide both strategic and scientific leadership opportunities and the opportunity to work across a broad span of functional areas including human genetics, human target validation, translational biology, biomarker discovery, clinical pharmacology, and clinical development and commercial strategy. This individual will have a strong influence on the shape and direction of Quotient’s drug discovery pipeline strategy, applying deep clinical insight to evaluate and prioritize somatic genomics-discovered drug targets, assets, and development plans across a wide range of disease areas.
This role would suit an MD or MD/PhD with a background in early clinical development within a pharma, biotech, or translational research setting who is comfortable working in a scientifically rich environment to help shape drug development programs from the earliest stages of discovery. As Quotient’s drug discovery pipeline expands, this individual will be expected to assume clinical leadership of Quotient’s Phase 1/2 clinical trials; working with CROs and a growing internal clinical development team.
Quotient Therapeutics is a privately-held, early stage company developing breakthrough medicines informed by natural somatic genetic diversity present in patients. Through our work in somatic genomics, we are forging a new status quo for biopharma research and development across a broad pipeline of internal and partnered programs.
The company was founded by Flagship Pioneering, an innovative enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Generate Biomedicines, Sana Biotechnology (SANA), Tessera Therapeutics, Evelo Biosciences (EVLO), Indigo Agriculture, Seres Therapeutics (MCRB), and Syros Pharmaceuticals (SYRS).
Quotient Therapeutics and Flagship Pioneering are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
#J-18808-Ljbffr
